A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

Inclusion Criteria: * Histologically or cytologically confirmed malignant disease * Scheduled to receive a single dose of one or more of moderately emetogenic chemotherapeutic agents during Cycle 1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 or Karnofsky score ≥60 * Predicted life span ≥4 months * Laboratory values demonstrating adequate hematologic status * Premenopausal females must not be pregnant or lactating and must agree to use effective birth control Exclusion Criteria: * Received chemotherapy within 6 months prior to starting on study drugs * Scheduled to receive subsequent treatment due to a refractory response to first or second line chemotherapy * Received an investigational drug within 30 days prior to starting on study drugs * Radiation therapy to the abdomen or pelvis in the week prior to starting on study drugs * Vomiting in the 24 hours prior to starting on study drugs * Active infection (e.g., pneumonia) or any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction) except for malignancy * Known hypersensitivity to Aprepitant (EMEND®), Dexamethasone or 5-HT3 receptor antagonists * Presentation with gastrointestinal obstruction symptoms * Symptomatic primary or metastatic central nervous system malignancy